Trial Profile
RESOLUTE-III all-comers trial: A randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESOLUTE-All comers; RESOLUTE-III All comers
- Sponsors Medtronic
- 05 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Jan 2014 Results published in the Journal of the American College of Cardiology.
- 04 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.